- Home
- TEM vs RVMD Comparison
TEM vs RVMD Comparison
Compare TEM & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEM
- RVMD
- Stock Information
- Founded
- TEM 2015
- RVMD 2014
- Country
- TEM United States
- RVMD United States
- Employees
- TEM N/A
- RVMD N/A
- Industry
- TEM
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TEM
- RVMD Health Care
- Exchange
- TEM NYSE
- RVMD Nasdaq
- Market Cap
- TEM 8.0B
- RVMD 8.7B
- IPO Year
- TEM 2024
- RVMD 2020
- Fundamental
- Price
- TEM $68.09
- RVMD $41.33
- Analyst Decision
- TEM Buy
- RVMD Strong Buy
- Analyst Count
- TEM 11
- RVMD 13
- Target Price
- TEM $59.60
- RVMD $65.15
- AVG Volume (30 Days)
- TEM 18.2M
- RVMD 1.2M
- Earning Date
- TEM 02-24-2025
- RVMD 02-26-2025
- Dividend Yield
- TEM N/A
- RVMD N/A
- EPS Growth
- TEM N/A
- RVMD N/A
- EPS
- TEM N/A
- RVMD N/A
- Revenue
- TEM $640,442,000.00
- RVMD $742,000.00
- Revenue This Year
- TEM $32.36
- RVMD N/A
- Revenue Next Year
- TEM $42.77
- RVMD $1,855.56
- P/E Ratio
- TEM N/A
- RVMD N/A
- Revenue Growth
- TEM 32.13
- RVMD N/A
- 52 Week Low
- TEM $22.89
- RVMD $28.95
- 52 Week High
- TEM $91.45
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- TEM N/A
- RVMD 44.66
- Support Level
- TEM N/A
- RVMD $40.13
- Resistance Level
- TEM N/A
- RVMD $42.68
- Average True Range (ATR)
- TEM 0.00
- RVMD 1.41
- MACD
- TEM 0.00
- RVMD 0.10
- Stochastic Oscillator
- TEM 0.00
- RVMD 26.42
About TEM TEMPUS AI INC
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.